

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/564,981
Filing Date	January 13, 2006
First Named Inventor	BAMDAD, Cynthia C.
Art Unit	1624
Examiner Name	MCDOWELL, Brian E.
Attorney Docket Number	13150-70090US

Sheet 1 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	CHEN et al., "Labeling of Proteins with [35S] Methionine and/or [35S] Cysteine in the Absence of Cells," Analytical Biochemistry, 269:179-188, 1999.	<input type="checkbox"/>
	C2	FRALEY et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", Trends in Biochemical Sciences, 6:77-80, 1981. (abstract only)	
	C3	GREGORIADIS, "Liposomes for drugs and vaccines," Trends in Biotechnology, 3(9):235-241, 1985. (abstract only)	
	C4	HIEKEN et al., "beta3 Integrin Expression in Melanoma Predicts Subsequent Metastasis," Journal of Surgical Research, 63(1):169-173(5), 1996. (abstract only)	
	C5	HORTON, "The alpha3beta3 Integrin "Vitronectin Receptor," Int. J. Biochem. Cell Biol., 29(5):721-725, 1997.	
	C6	KUFE et al., "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors," Hybridoma, 3(3):223-232, 1984. (abstract only)	
	C7	LIGTENBERG et al., "Cell-associated Episialin is a Complex Containing Two Proteins Derived from a Common Precursor", The Journal of Biological Chemistry, 267(9):6171-6177, 1992.	
	C8	MAO et al., "Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer," Int. J. Oncol., 18(3):587-591, 2001. (abstract only)	
	C9	MEERZAMAN et al., "Involvement of the MAP kinase ERK2 in MUC1 mucin signaling," Am. J. Physiol. Lung Cell Mol. Physiol., 281:L86-L91, 2001.	
	C10	PEGGRAM et al., "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment," Journal of Clinical Oncology, 16:2659-2671, 1998. (abstract only)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:****Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/564,981
Filing Date	January 13, 2006
First Named Inventor	BAMDAD, Cynthia C.
Art Unit	1624
Examiner Name	MCDOWELL, Brian E.
Attorney Docket Number	13150-70090US

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C11	ROSS et al., "The HER-2/neu Oncogene in breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy," Stem Cells, 16:413-428, 1998.	<input type="checkbox"/>
	C12	SAWHNEY et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly( $\alpha$ -hydroxy acid) Diacrylate Macromers," Macromolecules, 26:581-587, 1993.	
	C13	SCHNEIDER et al., "nm23 expression in advanced and borderline ovarian carcinoma," Anticancer Res., 16(3A):1197-1202, 1996. (abstract only)	
	C14	SPICER et al., "Molecular Cloning and Analysis of the Mouse Homologue of the Tumor-associated Mucin, MUC1, Reveals Conservation of Potential O-Glycosylation Sites, Transmembrane, and Cytoplasmic Domains and a Loss of Minisatellite-like Polymorphism," The Journal of Biological Chemistry, 266(23):15099-15109, 1991.	
	C15	TREON et al., "MUC-1 Core Protein is Expressed on Multiple Myeloma Cells and is Induced by Dexamethasone", Blood, 93(4):1287-1298, 1990. (abstract only)	
	C16	VAILHE et al., "In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to $\alpha(v)\beta 3$ integrin localization," In Vitro Cell Dev. Biol. Anim., 33(10):763-773, 1997. (abstract only)	
	C17	VARNER et al., "Integrins and cancer," Current Opinion in Cell Biology, 8:724-730, 1996.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:****Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.